The Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center (UNMC) division, was awarded a $362,741 Project Grant under the National Cancer Institute's (NCI) Cancer Treatment Research program (CFDA 93.395). The grant, awarded on July 9, 2024, aims to develop an "Ultra-Small Epigenetic-Regulating Nanocarrier for Enhanced Synthetic Lethal Therapy" to improve the efficacy of PARP inhibitor-based cancer treatments. Key objectives include optimizing a nanocarrier formulation that can effectively deliver a combination of the PARP inhibitor BMN673 and the DNA methylation inhibitor 5-azacytidine (AZA) to tumors, evaluating the pharmacokinetics and tumor penetration of the nanocarrier, and investigating its therapeutic efficacy and underlying mechanisms in non-small cell lung cancer models. This research seeks to expand the clinical use of synthetic lethal cancer therapy to both homologous recombination repair-deficient and proficient cancer types.
Generated 3/18/25, 1:44 AM